Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabiximols add-on therapy for multiple sclerosis spasticity
2019-002623-14Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Nabiximols add-on therapy with Placebo add-on therapy (2 arms). Primary endpoint: Change from baseline in average daily spasm count. Started Dec 2019; status: completed.
02
Drugs
cannabis extract
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-002623-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002623-14.